Patients’ experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson’s disease
Authors
- Anand R. Shewale (ORCID: https://orcid.org/0000-0002-3138-5623)
- Michael J. Soileau (ORCID: https://orcid.org/0000-0002-3944-1327)
- Jason Aldred (ORCID: https://orcid.org/0000-0001-7441-0967)
- Adwaita R. Parab (ORCID: https://orcid.org/0000-0001-9523-8908)
- Connie H. Yan (ORCID: https://orcid.org/0000-0003-1467-4666)
- Kailee White
- Maurizio Facheris (ORCID: https://orcid.org/0009-0002-4854-6873)
- Triza Brion (ORCID: https://orcid.org/0000-0002-5512-5420)
- Rajeev Kumar (ORCID: https://orcid.org/0000-0002-0783-1101)
- Megha Shah
- Pavnit Kukreja
Institutions
- Inland Northwest Health Services (US)
- AbbVie (United States) (US)
- Patient-Centered Outcomes Research Institute (US)
- Bioqual (US)
- Rocky Mountain MS Center (US)
- Southwestern University (US)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1007/s00415-025-13123-y
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- AbbVie